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Abstract
Background: Cardiac Troponin T (cTnT) elevation during exacerbations of chronic obstructive
pulmonary disease (COPD) is associated with increased mortality the first year after hospital
discharge. The factors associated with cTnT elevation in COPD are not known.
Methods: From our hospital's database, all patients admitted with COPD exacerbation in 2000–
03 were identified. 441 had measurement of cTnT performed. Levels of cTnT ≥ 0.04 μg/l were
considered elevated. Clinical and historical data were retrieved from patient records, hospital and
laboratory databases. Odds ratios for cTnT elevation were calculated using logistic regression.
Results: 120 patients (27%) had elevated cTnT levels. The covariates independently associated
with elevated cTnT were increasing neutrophil count, creatinine concentration, heart rate and
Cardiac Infarction Injury Score (CIIS), and decreasing hemoglobin concentration. The adjusted
odds ratios (95% confidence intervals in parentheses) for cTnT elevation were 1.52 (1.20–1.94) for
a 5 × 106/ml increase in neutrophils, 1.21 (1.12–1.32) for a 10 μmol/l increase in creatinine, 0.80
(0.69–0.92) for a 1 mg/dl increase in hemoglobin, 1.24 (1.09–1.42) for a 10 beats/minute increase
in heart rate and 1.44 (1.15–1.82) for a 10 point increase in CIIS.
Conclusion: Multiple factors are associated with cTnT elevation, probably reflecting the wide
panorama of comorbid conditions typically seen in COPD. The positive association between
neutrophils and cTnT elevation is compatible with the concept that an exaggerated inflammatory
response in COPD exacerbation may predispose for myocardial injury.
Background
Chronic Obstructive Pulmonary Disease (COPD) consti-
tutes an increasing health burden worldwide, and is the
only leading cause of death that still has a rising mortality
rate in industrialized countries.[1] In addition to a slow
progression of symptoms and deterioration of lung func-
tion, a large proportion of the patients experience epi-
sodes of symptom worsening, including increased
sputum, cough and dyspnea (exacerbations).[2] During
exacerbations, patients frequently need hospitalization,
and mortality is increased. Among COPD patients, cardi-
ovascular comorbidities are common, with congestive
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heart failure and ischemic heart disease estimated to
account for 10–40% of deaths.[3,4]
Cardiac troponins are established markers of myocardial
damage, and were included in the diagnostic criteria for
myocardial infarction in 2000.[5] Additionally, cardiac
troponin elevation is also seen in a variety of conditions
not directly related to flow-limiting coronary stenoses or
occlusion of the coronary arteries, such as pulmonary
embolism, septic shock, heart failure and stroke. [6-9] In
these settings, it is well documented that elevated circulat-
ing levels of troponins are associated with poor prognosis,
regardless of underlying disease.
In a historic cohort study of patients hospitalized for
COPD exacerbation, we found that patients with cardiac
troponin T (cTnT) ≥ 0.04 μg/l had a mortality rate nearly
twice as high as patients with no measurable cTnT in the
first year after discharge. [10]
With the exception of one other study,[11] sparse infor-
mation exists concerning the significance of troponin ele-
vation in COPD. Knowledge of determinants of troponin
elevation in COPD exacerbation may improve our under-
standing of underlying pathophysiological processes, and
ultimately, lead to improved therapeutic strategies.
Accordingly, the aim of this study is to identify the clini-
cal, biochemical and radiographic variables associated
with cTnT elevation during admission to hospital for
COPD exacerbation.
Methods
The study population consisted of patients admitted to
Akershus University Hospital, a 700-bed teaching hospital
that serves suburban and countryside regions, for COPD
exacerbation. Cases were identified using the hospital's
patient database. Patients aged 40 years or older admitted
during the four year period 1 January 2000 – 31 December
2003 and discharged with a primary diagnosis of COPD
exacerbation, ICD 10 (International Classification of Dis-
eases, 10th revision) code J44.0 or J44.1, or COPD (J44.x)
as an underlying diagnosis combined with pneumonia
(J13–J18.9) as the main diagnosis, were identified.
Patients with previous diagnoses of asthma, sarcoidosis,
interstitial lung disease, or neuromuscular disease were
excluded. For patients with more than one admission dur-
ing the inclusion period, the latest admission date was
used. 1087 admissions satisfied inclusion and exclusion
criteria. 41 patient records were not available for manual
review. 50 cases of erroneous ICD coding (5%) were dis-
covered during manual record review.
Of the 996 patients identified, we included the 441
patients from whom cTnT was sampled within the first 24
hours of admission in the current investigation. The deci-
sion to sample cTnT was made in the emergency room
(ER) at the discretion of the physician on call, and was
thus non-random. This selection process has been ana-
lysed and discussed in a previous paper where we used a
propensity score model to adjust for possible sampling
bias. [10]
Results from the first two rounds of laboratory analyses
performed within 24 hours from the time of hospital
admission were retrieved from the hospital's laboratory
database, 86% of results were from the first set of blood
samples obtained at presentation, before treatment was
instigated. For white blood cell count (WBC), results from
the first round of samples were used. Otherwise, when
multiple results were available, average hemoglobin con-
centrations (Hb), maximum cTnT and C-reactive protein
(CRP), and minimum creatinine values were used. WBC
was divided into neutrophil count and non-neutrophil
count.
The cTnT assay used by the hospital laboratory was Elecsys
Troponin T STAT (Roche Diagnostics GmbH, Mannheim,
Germany), the serum creatinine assay was an Ortho Vitros
Crea enzymatic slide method, range 4–1238 μmol/L, CV
2.0% at 70 μmol/L (Ortho Clinical Diagnostics, Roches-
ter, NY), C-reactive protein was analysed using a particle-
enhanced turbidimetric immunoassay with a CV of 2–4%
in the range of 0–300 mg/L, upper reference: 7 mg/L
(Roche Diagnostics GmbH, Mannheim, Germany).
Hematology analysis was performed on a Sysmex XE 2100
(Sysmex Europe GmbH, Norderstedt, Germany). Anemia
was defined as Hb concentration < 12 mg/dl if female, <
13 mg/dl if male.
cTnT was considered elevated at levels equal to or greater
than 0.04 μg/l, at which point the assay has less than 10%
coefficient of variation (personal communication with
our hospital laboratory), which is the cut-off criterium
recommended by the ESC/ACC.[5] Hospital policy at that
time recommended a cTnT concentration of 0.10 μg/l or
higher as the diagnostic threshold for myocardial infarc-
tion (MI). The detection limit for cTnT was 0.01 μg/l.
Patient data from ER presentation, including oxygenation
measured by pulse oximetry, supplemental oxygen flow,
arterial blood gas analysis (pO2, pCO2, pH), blood pres-
sure, and respiratory frequency, in addition to medication
use on admission and at discharge, were manually gath-
ered from hospital records.
ECGs recorded on admission were retrieved from patients'
records, and manually scored according to a Cardiac Inf-
arction Injury Score (CIIS) algorithm modified for visual
coding.[12] Heart rate and rhythm were gathered from the
ECG. Coders were blinded to other clinical data.BMC Pulmonary Medicine 2009, 9:35 http://www.biomedcentral.com/1471-2466/9/35
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Spirometry data, if performed in a stable state at least one
week before or four weeks after hospital discharge, were
gathered from patient records. Forced vital capacity (FVC),
expiratory volume in one second (FEV1) are expressed as
percent of predicted using the European Community for
Steel and Coal equations.[13]
Available chest radiographs from the date of admission
were re-examined in co-operation by two physicians (VS
and SHH), who were blinded regarding clinical data. The
following parameters were evaluated: Cardiomegaly (car-
diothoracic ratio > 50%), hyperinflation, pneumonic
infiltrates, and pulmonary congestion.
Discharge ICD codes entered for each patient since 1987,
until but not including the date of admission, were
obtained from the hospital database. For each patient,
groups of codes were used to construct a history of cancer,
diabetes, hypertension, MI, congestive heart failure and
venous thromboembolism. Additionally, each patient's
medical records were manually searched for information
on comorbid conditions.
The study was approved by The Data Inspectorate and the
Regional Committee for Research Ethics.
Statistical analyses
Chi-square test were used for between-group comparisons
in univariate analyses on dichotomous variables (table 1),
and univariate logistic regression was used for continuous
variables. For descriptive purposes, continuous variables
are shown as quartiles in table 2. In all regression models,
however, these variables were used in their original form.
The multiple logistic regression model was built according
to a purposeful variable selection method outlined by
Hosmer and Lemeshow. [14] Briefly, all variables that
were associated with cTnT elevation by univariate tests
with a p-value equal to or less than 0.20 were included in
the initial multivariate logistic regression model. This was
then manually simplified by removing clearly non-signif-
icant covariates while for each step comparing the simpler
model to the larger one using the likelihood ratio chi-
square test and ensuring that variable removal did not
meaningfully change the estimates for other important
covariates. Continuous variables were tested for linearity
in the logit by using design variables. All variables not ini-
tially included were tested for significance in the prelimi-
nary main effects model before testing for clinically
interesting interactions. Finally, goodness of fit of the
model was assessed using the Hosmer-Lemeshow test.
Results of the regression are reported as odds ratios (OR),
with 95% confidence intervals (CI) in parentheses.
Results
The mean age of patients included in the study was 72.2
years (standard deviation 10.7), 49% were female. Ele-
vated cTnT was found in 27% of patients. Coexisting car-
diovascular conditions were common, with 24% of the
patients having a diagnosis of arterial hypertension, 22%
having a history of previous MI, 16% having diabetes mel-
litus, and 13% having a diagnosis of congestive heart fail-
ure. Spirometry data were available in 333 (76%) of
patients. Mean FEV1 (pre-bronchodilator) was 48% of
predicted, and mean FEV1/FVC-ratio was 0.67.
Univariate analyses identified clinical, laboratory and
demographic variables associated with elevated cTnT lev-
els, and results are presented in tables 1 and 2. Several
markers of infection or inflammation (CRP, neutrophil
count, infiltrate) were strongly associated with cTnT eleva-
tion, as were markers of heart disease (CIIS, radiographic
cardiomegaly, radiographic signs of congestion, history of
MI, heart failure or diabetes) as well as use of some drugs
Table 1: Dichotomous variables as number of subjects, n (%), 
with elevated vs non-elevated cTnT, with p-values from chi 
square tests.
Characteristic cTnT = 0.04
(n≥ 120)
cTnT < 0.04
(n = 321)
p-value
Gender
Female 51 (43) 166 (52) 0.09
ECG
Atrial fibrillation 20 (17) 34 (11) 0.08
Chest radiograph
Hyperinflation 31 (26) 99 (31) 0.31
Infiltrate 50 (43) 77 (27) 0.001
Cardiomegaly 69 (58) 111 (35) < 0.001
Congestion (any sign) 53 (44) 94 (29) 0.003
Medical history
Myocardial infarction 35 (33) 58 (19) 0.002
Heart failure 31 (26) 27 (8) < 0.001
Diabetes 29 (24) 41 (13) 0.004
Hypertension 32 (27) 75 (23) 0.47
Thromboembolism 4 (3) 11 (3) 0.96
Cancer 17 (14) 41 (13) 0.7
Treatment
LTOT 9 (8) 27 (9) 0.86
Inhaled beta2-agonists 91 (86) 250 (88) 0.62
Inhaled corticosteroids 60 (55) 202 (66) 0.04
Warfarin 16 (15) 33 (11) 0.30
Aspirin 45 (38) 93 (29) 0.09
ACE inhibitors 32 (29) 63 (21) 0.07
Beta-blockers 18 (16) 52 (17) 0.88
Statins 15 (13) 55 (17) 0.24
ACE – Angiotensin converting enzyme; ECG – Electrocardiogram; 
LTOT – Long term oxygen therapyBMC Pulmonary Medicine 2009, 9:35 http://www.biomedcentral.com/1471-2466/9/35
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targeting the cardiovascular system (aspirin and angi-
otensin converting enzyme inhibitors) and inhaled corti-
costeroids. Use of beta-blockers or inhaled beta-agonists
were not significantly associated with cTnT elevation, nor
were history of hypertension, previous thromboembolic
disease, pH, body temperature or non-neutrophil count.
Since increased neutrophil count is associated with infec-
tion, we investigated the possibility of an interaction
between neutrophil count and the presence of a pneu-
monic infiltrate on the chest radiograph. The product
term added to the preliminary main effects model was
non-significant (p = 0.95).
After manual reduction of the logistic regression model,
the covariates with significant independent associations
with elevated cTnT were increasing creatinine concentra-
tion, neutrophil count, heart rate and CIIS points, and
decreasing Hb. Adjusted ORs with corresponding 95% CIs
are presented in Table 3. Eight patients were diagnosed
with acute MI during the index hospitalisation. Removing
these patients from the analysis produced negligible
changes in the estimates in the final model.
The final model satisfied the Hosmer-Lemeshow test for
goodness of fit, but exploring model diagnostics and coef-
ficients for stratified variables revealed that the effect of
heart rate was not entirely linear. While a better fitting
model for heart rate data was achieved when eliminating
patients with atrial fibrillation from the regression, this
reduced model caused only marginal changes in the effect
estimates for covariates at the third significant digit, with
the exception of neutrophil count (OR: 1.42 (1.10–1.83)
for a 5 × 106/ml increase). Thus, the model presented in
Table 2: Continuous variables as number of subjects per quartile with elevated cTnT. 
Quartiles
Characteristic First Second Third Fourth p
Age, years < 64 64–73 74–80 > 80
n (%) 18 (17) 27 (25) 37 (32) 38 (34) < 0.001
Heart rate, beats/minute < 84 84–97 98–110 > 110
n (%) 16 (15) 29 (29) 31 (29) 40 (40) 0.001
CIIS, points < 6 6–13 14–22 > 22
n (%) 17 (15) 22 (23) 34 (36) 43 (40) < 0.001
Systolic blood pressure, mmHg < 120 120–139 140–157 > 157
n (%) 45 (41) 24 (24) 20 (21) 22 (20) 0.001
Diastolic blood pressure, mmHg < 65 65–76 77–88 > 88
n (%) 44 (37) 26 (27) 14(15) 26 (25) 0.002
Temperature, °C < 36.7 36.7–37.4 37.5–38.1 > 38.1
n (%) 26 (22) 37 (35) 18 (23) 27 (27) 0.9
Respiratory rate, breaths/min < 21 21–25 26–30 > 30
n (%) 10 (26) 11 (27) 9 (17) 20 (40) 0.04
Oxygen saturation, % < 88 88–92 93–95 >95
n (%) 25 (32) 18 (25) 21 (22) 20 (29) 0.06
pCO2, kPa < 4.8 4.8–5.5 5.6–6.7 > 6.7
n (%) 27 (26) 22 (22) 21 (24) 32 (36) 0.04
pH < 7.38 7.38–7.42 7.43–7.46 > 7.46
n (%) 42 (36) 13 (17) 26 (23) 21 (30) 0.10
FEV1, % of predicted < 31 31–42 43–58 > 58
n (%) 24 (33) 26 (33) 22 (26) 19 (20) 0.06
Creatinine, μmol/l < 62 62–76 77–97 > 97
n (%) 19 (18) 16 (16) 29 (30) 56 (44) < 0.001
CRP, mg/l < 13 13–56 57–163 > 163
n (%) 21 (20) 24 (24) 27 (24) 47 (43) 0.001
Neutrophil count, 106/ml < 5.8 5.8–8.3 8.4–11.7 > 11.7
n (%) 14 (17) 26 (21) 30 (27) 50 (41) < 0.001
Non-neutrophil count, 106/ml < 1.5 1.5–2 2.1–2.8 > 2.8
n (%) 40 (34) 19 (26) 21 (23) 23 (26) 0.11
Hemoglobin, mg/dl < 11.8 11.8–13.1 13.2–14.2 > 14.2
n (%) 49 (40) 33 (31) 16 (13) 22 (24) < 0.001
P-values from univariate logistic regression.
CIIS – Cardiac infarction injury score; CRP – C-reactive protein; FEV1 – Forced expiratory volume in 1 secondBMC Pulmonary Medicine 2009, 9:35 http://www.biomedcentral.com/1471-2466/9/35
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Table 3 is for the complete cohort. Neither age, gender nor
pulmonary function were significantly associated with
cTnT elevation in the multivariate model.
Due to the historic nature of the data, it is difficult to
assess whether cTnT elevations represent an acute MI or
not. However, by restricting the final model to patients
with only marginally elevated cTnT concentrations, above
the detection limit of 0.04 μg/L but below a commonly
used MI decision level of 0.10 μg/L, most if not all patients
with an acute MI should be excluded. This restricted
model, while having less statistical power and rendering
several covariates marginally significant, resulted in lim-
ited changes in the effect estimates. Neutrophil count
remained highly significant in the restricted model.
Discussion
The important new information derived from the present
study is that multiple, apparently unrelated factors are
associated with increased cTnT levels in patients hospital-
ized for COPD exacerbation. Accordingly, factors believed
to signify coronary artery disease, tachycardia, renal
impairment and anemia all contribute to cTnT elevation.
Interestingly, neutrophils, which are the cells that charac-
terize COPD exacerbations, were positively associated
with cTnT elevation in a dose-response manner. Given
that cTnT is a strong, independent predictor of adverse
outcome in patients with COPD exacerbation,[10] these
results suggest that cTnT levels reflect and integrate prog-
nostic information from different, harmful pathophysio-
logical processes.
In human myocardium, cTnT is mostly bound to the
myofibrils, but approximately 6% is found in solution in
the cytosol. Traditionally, troponins have been consid-
ered markers of myocardial cell necrosis. However, several
studies have shown a biphasic or rapid rise and fall of tro-
ponins in response to short term myocardial ischemia,
suggesting that some of the circulating troponins may
stem from reversible cell damage, probably representing
the cytosolic fraction.[15,16] The restricted version of the
final model, which includes only patients with a cTnT
concentration highly unlikely to represent an acute MI,
did not differ appreciably from the full model in effects
estimates, but the lower statistical power rendered most
covariates marginally significant. Neutrophil count
remained highly significant. While we do not have follow-
up troponin measurements from later in the hospital stay,
the authors believe it is unlikely that the low levels of cir-
culating cTnT observed in the present study reflect major
ischemic events or occlusion of significant coronary arter-
ies. Rather, our results suggest they may result from the
total burden of multiple comorbidities in addition to the
circulatory and respiratory strain of the COPD exacerba-
tion itself.
There are multiple mechanisms which may account for
the cTnT elevations observed in the present study. In the
setting of a COPD exacerbation, arterial hypoxemia, tach-
ycardia as well as anemia may cause a supply-demand
mismatch in susceptible tissues, resulting in cardiomyo-
cyte injury. These mechanisms may be applicable in
patients with established coronary artery disease.[17] Per-
haps surprisingly, our multivariate analyses did not con-
firm any significant association between arterial
hypoxemia and cTnT elevation. Patients may have had
more severe hypoxemia prior to hospitalization. The asso-
ciations with anemia and tachycardia, however, are in
agreement with previous studies.[18,19] In a similar man-
ner, our study confirms the association between cTnT ele-
vation and renal dysfunction.[20,21]
The association with an elevated neutrophil count may
deserve particular attention. COPD is characterized by
pronounced neutrophil inflammation of the airways, and
during disease exacerbations there is a flaring of the
inflammatory response, both locally and systemi-
cally.[22,23] A "spill-over" effect from the lungs to the sys-
temic and cardiac vasculature is conceivable, possibly
amplifying the inflammatory processes in atherosclerosis
and atherothrombosis.[4,24] Interestingly, there was no
sign of interaction between neutrophil inflammation and
Table 3: Results of multivariate logistic regression model. Adjusted odds ratios (OR), with 95% confidence intervals (CI), for elevated 
cTnT according to patient characteristic.
Full final model
(cTnT ≥ 0.04, n = 344)
Restricted final model
(cTnT 0.04 – 0.09, n = 263)
Characteristic OR 95% CI OR 95% CI
Creatinine + 10 (μmol/l) 1.21 1.12 – 1.32 1.11 0.99 – 1.94
Hemoglobin +1 (mg/dl) 0.80 0.69 – 0.92 0.84 0.71 – 1.00
Neutrophil count + 5 (106/ml) 1.52 1.20 – 1.94 1.48 1.13 – 1.94
Heart rate + 10 (beats/minute) 1.24 1.09 – 1.42 1.17 1.00 – 1.36
CIIS +10 (points) 1.45 1.15 – 1.82 1.25 0.95 – 1.64
Odds ratios are adjusted for all other variables in the table.
CIIS – Cardiac infarction injury score.BMC Pulmonary Medicine 2009, 9:35 http://www.biomedcentral.com/1471-2466/9/35
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pneumonic infiltrates, suggesting that the mechanism is
independent of infection. Indeed, increased circulating
neutrophils have been implicated in myocardial damage
through several mechanisms – including the secretion of
large amounts of inflammatory mediators, activation of
the coagulation system, oxidative vascular damage or even
abnormal aggregation and vessel plugging.[25] Since ster-
oid therapy may influence the WBC, we used only analysis
results from the initial ER presentation, when blood sam-
ples are routinely drawn before therapy is started. Some
patients may, however, have started treatment of the exac-
erbation prior to hospitalization and thus have an 'artifi-
cially' increased WBC. This we have no way to control for,
and the direction of bias is hard to determine: If patients
with more severe disease are more likely to start steroids
prior to hospitalisation, and have a higher risk of cTnT ele-
vation, it would tend to strengthen the observed relation-
ship between cTnT and WBC. On the other hand, studies
on steroid use in COPD suggest a cardioprotective
effect,[26,27] and pre-hospital steroid use would then
tend to obscure the association between WBC and ele-
vated cTnT, meaning that the true association may be
stronger than our estimates.
The CIIS system was developed to improve the diagnosis
of MI, and at score of 20 points has a sensitivity and spe-
cificity for detecting MI of 85% and 95%, respectively.[28]
CIIS has been shown to be the best of several ECG scoring
systems for determining risk of cardiovascular mortality
[29] – additionally, the score has been shown to be
inversely correlated with FEV1,[30] and carries independ-
ent prognostic information in COPD.[31] In the present
study, we interpret CIIS as a better marker of established
coronary artery disease in COPD patients than ICD diag-
nostic codes or history from medical records. In the final
multivariate regression analysis, the inclusion of CIIS ren-
dered the other covariates associated with a history of car-
diovascular disease completely insignificant.
In our material, 27% of patients had elevated circulating
cTnT. This is very close to the 25% prevalence found by
Harvey and Hancox,[32] and comparable to the study by
Baillard et al where they reported that 18% of their
patients had elevated troponin I.[11] However, since cTnT
in our study was measured in less than half of patients
with COPD exacerbation, a selection of patients with an
increased likelihood of troponin elevation is likely, thus
resulting in our estimate of the prevalence of cTnT eleva-
tion probably being an overestimate of the true preva-
lence among patients hospitalized for COPD
exacerbation. We have previously shown in a propensity
score model on the same dataset that patients with
reduced FEV1 or hyperinflation on chest radiograph had a
lower probability of cTnT sampling, whereas a history of
ischemic heart disease, use of aspirin, or radiographic
signs of pulmonary congestion increased the probability
of cTnT measurement. Mortality, however, was only mar-
ginally different between patients who did and did not
have cTnT sampled.[10] This illustrates the difficulty in
distinguising between COPD patients with higher and
lower risks of myocardial damage in clinical practice, and
indirectly supports the external validity of the present
results.
The major methodological limitation of the present study
is the cross-sectional design, which does not permit causal
inferences to be made. Additionally, the historic nature of
the data means that several interesting measurements pos-
sibly associated with cTnT elevation are unavailable, such
as B-type Natriuretic Peptide or echocardiographic data
for better classification of heart failure, or CT scans to
diagnose pulmonary embolism. Finally, whether cTnT
elevation in COPD exacerbations reflects an acute MI or is
caused by other factors is difficult to establish without cor-
onary imaging. The authors believe, however, that we
have been able to account for significant factors using
proxy variables and restricted analyses.
The diagnosis of COPD in this study was made at dis-
charge, based on all available clinical data. Frequently,
deciding whether or not COPD exacerbations are accom-
panied by pneumonia is difficult. Thus, we included
patients coded with pneumonia as the main diagnosis
and COPD as the underlying diagnosis. Testing for inter-
action revealed no significant difference in determinants
of cTnT elevation for patients with pneumonic infiltrates
compared to those without. A physician specialized in
internal medicine or pulmonary medicine verified the
diagnoses at the time of hospital discharge. While the
diagnosis was not based on specific criteria such as sug-
gested by the Global initiative for chronic Obstructive
Lung Disease (GOLD), we consider the study population
to be well defined, and representative of COPD patients
seen in pulmonary care units in Western countries [33].
Clinical implications
Given the prognostic implications of cTnT elevation, fur-
ther diagnostic and therapeutic measures directed toward
patients presenting with risk factors for cTnT elevation
may be warranted. Intensified surveillance and treatment
of anemia and tachycardia, and increased diagnostic and
secondary prevention efforts in patients with markers of
coronary artery disease could potentially reduce the inci-
dence of troponin elevation in COPD exacerbation. How-
ever, considering the multiple factors involved in cTnT
elevation, interpretation of low grade cTnT elevation in a
COPD population should be done with caution. Elevated
cTnT in isolation should not be considered diagnostic of
an acute MI, or an indication for angiography. That said,BMC Pulmonary Medicine 2009, 9:35 http://www.biomedcentral.com/1471-2466/9/35
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the angiographic correlates of cTnT elevation in COPD
remain to be elucidated.
As to the neutrophil count, given that systemic and cardiac
inflammatory responses are caused or exacerbated by the
local inflammation associated with COPD, there is a pos-
sibility of mitigating that response through local treat-
ment. At least two papers have shown that inhaled
corticosteroid use in COPD causes reduction in systemic
markers of inflammation.[34,35] Most intriguingly, a
study of therapy with corticosteroids by Huiart et al indi-
cated a 32% reduction in the risk of acute MI (p < 0.05)
for patients using 50–200 μg per day of inhaled beclom-
ethasone or equivalent,[26] and a post hoc analysis of the
European Respiratory Society's study on Chronic Obstruc-
tive Pulmonary Disease (EUROSCOP) trial showed that
smokers with mild COPD treated with inhaled budeso-
nide 800 μg/day had a significantly lower incidence of
ischemic cardiac events compared to patients receiving
placebo.[27]
Conclusion
The present study suggests a multifactorial explanation for
the cTnT elevation seen in COPD exacerbation, partly
reflecting the many comorbid conditions seen in COPD.
The positive association between neutrophils and cTnT
elevation is compatible with the concept that an exagger-
ated inflammatory response in COPD exacerbation pre-
disposes for myocardial injury.
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